Chilmark Research October 15, 2020
Jody Ranck

While COVID-19 has been dominating the healthcare headlines so far in 2020 there have been a number of recent policy and regulatory decisions bearing on the AI/ML market in healthcare. We have been reading quite a bit about the broader slowdown in the market for AI/ML developers since the pandemic began that may be a temporary disruption to some parts of the market. On the other hand, CMS and the FDA have made some moves that may be part of building a stronger foundation for the market in AI applications, at least in clinical decision support and radiology/medical imaging segments of the market. We have also seen some major bets placed on AI-based companies that are riding on the wave...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), CMS, FDA, Govt Agencies, Healthcare System, Investments, Public Health / COVID, Regulations, Technology, Trends
Related Articles:
STAT+: After AI protein folding, David Baker’s lab identifies millions of smaller drug candidates
Alphabet shares jump 14% on earnings beat, first-ever dividend
Microsoft: Unlocking AI Benefits Will Require Cultural Changes for Enterprises
Zephyr AI Raises $111 Million in Series A Financing
Chatbot answers are all made up. This new tool helps you figure out which ones to trust.

Share This Article